101376-26-5 Usage
Description
(R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE is a morpholine derivative characterized by the presence of a benzyl group at the fourth carbon and a hydroxymethyl group at the third carbon of the morpholine ring. This unique structure endows it with potential pharmaceutical applications, making it a valuable building block in the synthesis of various drugs and pharmaceuticals. Furthermore, it has demonstrated potential as a chiral auxiliary for asymmetric synthesis, which is significant in the pharmaceutical and chemical industries.
Uses
Used in Pharmaceutical Industry:
(R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE is used as a building block for the synthesis of various drugs and pharmaceuticals due to its unique structure and properties. Its presence in the molecular framework can contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Asymmetric Synthesis:
(R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE is used as a chiral auxiliary in asymmetric synthesis for the production of enantiomerically pure compounds. Its ability to induce chirality in the synthesis process is valuable for creating pharmaceuticals with specific biological activities, as the stereochemistry of a molecule can significantly influence its pharmacological properties.
Used in Chemical Industry:
(R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE is utilized in the chemical industry for the development of novel compounds and materials. Its unique structural features make it an interesting target for further study and development, potentially leading to the creation of new chemical entities with diverse applications in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 101376-26-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,3,7 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 101376-26:
(8*1)+(7*0)+(6*1)+(5*3)+(4*7)+(3*6)+(2*2)+(1*6)=85
85 % 10 = 5
So 101376-26-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H17NO2/c14-9-12-10-15-7-6-13(12)8-11-4-2-1-3-5-11/h1-5,12,14H,6-10H2/t12-/m1/s1
101376-26-5Relevant articles and documents
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor
Borsari, Chiara,Rageot, Denise,Dall'Asen, Alix,Bohnacker, Thomas,Melone, Anna,Sele, Alexander M.,Jackson, Eileen,Langlois, Jean-Baptiste,Beaufils, Florent,Hebeisen, Paul,Fabbro, Doriano,Hillmann, Petra,Wymann, Matthias P.
, p. 8609 - 8630 (2019/10/16)
The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.
NOVEL HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 48; 49, (2013/07/05)
The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
